Xenon Prescribed drugs CFO sells shares price $770,911

In a current transaction reported to the Securities and Trade Fee, Sherry Aulin, the Chief Monetary Officer of Xenon Prescribed drugs Inc. (NASDAQ:XENE), offered a good portion of her holdings within the firm. In response to InvestingPro information, Xenon, at the moment valued at $2.97 billion, has proven sturdy monetary well being with a outstanding present ratio of twenty-two.21, indicating sturdy liquidity. The transactions occurred on December 18, 2024, involving the sale of 18,709 frequent shares at costs starting from $41.19 to $41.23, totaling $770,911.

The submitting additionally detailed that Aulin exercised inventory choices to accumulate 25,334 frequent shares at costs starting from $9.44 to $11.58, amounting to a complete acquisition worth of $273,392. Moreover, shares have been disposed of for tax obligations at a value of $41.28, leading to a complete of $273,480 for these transactions.

These transactions replicate Aulin’s strategic monetary selections relating to her fairness in Xenon Prescribed drugs, which makes a speciality of pharmaceutical preparations. The corporate’s shares are traded on the NASDAQ below the ticker XENE. Whereas the corporate is not at the moment worthwhile, InvestingPro evaluation reveals 7 extra key insights about XENE’s monetary place and development prospects, accessible within the complete Professional Analysis Report.

In different current information, Xenon Prescribed drugs has been making vital strides within the biopharmaceutical trade, catching the eye of a number of analyst corporations. H.C. Wainwright reiterated their Purchase ranking on Xenon shares, sustaining a value goal of $53. This ranking is primarily influenced by the promising potential of Xenon’s new antiseizure treatment, azetukalner, and the corporate’s plans to file a number of Investigational New Drug purposes in 2025.

RBC Capital additionally echoed a constructive sentiment, sustaining an Outperform ranking and elevating the worth goal to $56, reflecting optimistic expectations for Xenon’s upcoming medical information releases. Xenon’s third-quarter 2024 monetary outcomes highlighted sturdy efficacy information for azetukalner in epilepsy, together with vital enhancements in seizure frequency and affected person high quality of life. The corporate ended the quarter with a money stability of $803.3 million, projecting ample funding into 2027.

The corporate’s strategic concentrate on creating revolutionary therapies for epilepsy and main depressive dysfunction (MDD) is clear of their current developments. Xenon plans to provoke a Part 3 program for MDD earlier than the top of 2024 and expects Part 3 epilepsy program ends in the latter half of 2025. The corporate can also be progressing its Nav1.7 sodium channel program, with IND filings anticipated in 2025.

This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.